Vicore Pharma (Group)

https://www.vicorepharma.com

LinkedIn: https://www.linkedin.com/company/vicore-pharma-ab

We are an innovative Swedish research and development company dedicated to creating life-changing treatments for rare lung diseases. Embedded in our approach is the determination to find solutions for conditions which have an enormous deleterious impact on patients and their families and to transform the lives of those affected. Patients with rare fibrotic lung diseases can suffer from progressive difficulty in breathing and a relentless deterioration in quality of life. Receiving such a diagnosis can be devastating, due to the poor prognosis. We appreciate that living with such diseases presents a constant challenge, not only for patients but also for their families and caregivers. Our research and drug development programmes are specifically aimed at alleviating these challenges with the patient at the forefront of our minds. From early days to the present We were founded in 2000, following research at Uppsala University and the Sahlgrenska Academy, and originally funded by venture capital. In December 2015, the Company completed an equity issue and was publicly listed on Nasdaq First North. In the summer of 2018, with new Venture Capitalist backing from HealthCap, Vicore Pharma further strengthened its financial position. With the new funding, these transformational medicines can be effectively moved closer to patients. In September 2019 Vicore Pharma listed its shares on Nasdaq Stockholm. *

	Start	2001-01-01 existent
	Industry	pharmaceutical
	Person	Dalsgaard, Carl-Johan (Cardoz AB 201108 CEO)

	Region	Göteborg (Gothenburg)
	Country	Sweden
	Street	11 Kronhusgatan
	City	41105 Göteborg
	Tel	+46-31-788-0560
		Address record changed: 2024-01-05

Basic data	Employees	B: 11 to 50 (2020-12-31)
	Currency	SEK
	Profit	-146,862,000 (2020-12-31)
	Cash	248,618,000 (2020-12-31)

		�About Section� taken from web site of organisation on 28.08.

		Record changed: 2024-02-12

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]